Welcome to our dedicated page for Biocryst Pharmaceuticals news (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals stock.
BioCryst Pharmaceuticals Inc (BCRX) is a biotechnology leader developing innovative therapies for rare diseases and infectious conditions through targeted enzyme inhibition. This news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access authoritative reporting on BCRX's pipeline progress, including updates on hereditary angioedema treatments and antiviral therapies. Our curated collection features earnings announcements, research breakthroughs, and partnership disclosures – all essential for tracking this biopharma innovator.
Key updates include FDA decisions, clinical trial results, and scientific publications. Bookmark this page for streamlined access to verified BioCryst news, eliminating the need to monitor multiple sources. Check regularly for developments impacting the company's position in enzyme inhibitor therapeutics and rare disease treatment markets.
BioCryst Pharmaceuticals (BCRX) has granted stock options and restricted stock units (RSUs) to eight newly-hired employees as employment inducements. The compensation committee approved options to purchase 22,575 shares and RSUs covering 27,550 shares of common stock, effective January 31, 2025.
The stock options were granted at an exercise price of $7.90 per share, matching the closing price on the grant date. Both options and RSUs will vest in four equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. The stock options have a 10-year term and are subject to BioCryst's Inducement Equity Incentive Plan terms.
BioCryst Pharmaceuticals reported preliminary ORLADEYO® net revenue of $437 million for 2024, marking a 34% year-over-year growth. The company expects ORLADEYO revenue between $515-$535 million and total revenue of $540-$560 million in 2025.
Key highlights include achieving operating profit in 2024 (excluding stock-based compensation) and projecting quarterly EPS profitability/positive cash flow in 2H 2025. The company plans a new drug application in 2025 for ORLADEYO granules for children under 12.
Q4 2024 ORLADEYO net revenue reached $123.5 million (+36% y-o-y), with total revenue of $130.8 million (+40% y-o-y). Over 1,200 U.S. physicians have prescribed ORLADEYO across 30+ countries. The company expects 2025 GAAP operating expenses between $485-495 million, including $60 million in stock-based compensation.
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for Tuesday, January 14, 2025, at 6:00 p.m. ET. Interested parties can access both the live audio webcast and a replay of the presentation through the Investors & Media section on BioCryst's official website (www.biocryst.com).
BioCryst Pharmaceuticals (Nasdaq: BCRX) has announced inducement grants for 10 newly-hired employees. The compensation committee approved stock options to purchase 52,750 shares and restricted stock units (RSUs) covering 36,975 shares of BioCryst common stock, granted on December 31, 2024.
The stock options have an exercise price of $7.52 per share, matching the closing price on the grant date. Both options and RSUs will vest in four equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. The stock options have a 10-year term and were granted under Nasdaq Listing Rule 5635(c)(4) as employment inducements.
BioCryst Pharmaceuticals (BCRX) has granted stock-based compensation to five newly-hired employees as employment inducements. The package includes stock options to purchase 17,400 shares and restricted stock units (RSUs) covering 12,150 shares of common stock. The options were granted at an exercise price of $7.50 per share, matching the closing price on November 29, 2024.
Both options and RSUs will vest over four equal annual installments, starting from the one-year anniversary of the grant date, contingent on continued employment. The stock options have a 10-year term and were granted under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that Ireland's Health Services Executive (HSE) has recommended ORLADEYO (berotralstat) for routine prevention of hereditary angioedema (HAE) attacks in patients 12 years and older. This marks the introduction of the first oral, once-daily therapy for HAE attack reduction in Ireland. The recommendation follows the European Commission's marketing authorization granted in April 2021. ORLADEYO is currently licensed in 44 countries.
BioCryst Pharmaceuticals (BCRX) has announced its participation in three upcoming investor conferences. The company will present at the 2024 Jefferies London Healthcare Conference on November 20 at 5:00 a.m. ET, the 7th Annual Evercore HealthCONx Conference in Coral Gables on December 4 at 2:35 p.m. ET, and the Piper Sandler 36th Annual Healthcare Conference in New York on December 5 at 8:30 a.m. ET. Live audio webcasts and replays will be available through BioCryst's website investor section.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced inducement grants for five newly-hired employees. The compensation package includes stock options to purchase 18,200 shares at $8.01 per share and restricted stock units (RSUs) covering 12,750 shares. Both options and RSUs will vest over four equal annual installments starting one year from the October 31, 2024 grant date. The stock options have a 10-year term, and all grants were made under Nasdaq Listing Rule 5635(c)(4) as employment inducements.
BioCryst Pharmaceuticals reported strong Q3 2024 financial results, with ORLADEYO net revenue reaching $116.3 million, a 35.7% year-over-year increase. The company achieved a GAAP operating profit of $7.7 million and adjusted its full-year 2024 ORLADEYO revenue guidance to $430-435 million. Total product revenue guidance for 2024 is set at $443-448 million. The company reported progress with BCX17725 for Netherton syndrome entering clinical trials and expects to be approaching quarterly positive EPS by second half of 2025.
BioCryst Pharmaceuticals presented new real-world evidence for ORLADEYO® (berotralstat), showing high adherence and persistence rates comparable to other HAE long-term prophylactic therapies. The study revealed that 86% of ORLADEYO patients filled at least two prescriptions, with 77% adherence and 71% persistence rates at 12 months.
Additional data demonstrated significant HAE attack rate reductions after ORLADEYO initiation, regardless of C1-inhibitor status. Patient survey results indicated a preference for oral therapy, with 54% choosing oral daily treatment over injectable options when efficacy is equal.
